Two autologous anti‐CD19 chimeric antigen receptors (CAR) T cells (axicabtagene
ciloleucel [axi‐cel] and tisagenlecleucel [tisa‐cel]) are commercially approved in Europe for …

Anti-CD19 chimeric antigen receptor (CAR) T-cells represent a major advance in the
treatment of relapsed/refractory aggressive B-cell lymphomas. However, a significant …

Introduction Axi-cel is an autologous anti-CD19 CAR T-cell therapy approved by the US FDA
10/18/2017, for the treatment of adults with relapsed or refractory (r/r) large B-cell lymphoma …

Axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) are CD19-targeted chimeric
antigen receptor (CAR) T cells approved for relapsed/refractory (R/R) large B-cell lymphoma …

CD19-directed chimeric antigen receptor (CAR) T cells have evolved as a new standard-of-
care (SOC) treatment in patients with relapsed/refractory (r/r) large B-cell lymphoma (LBCL) …

Increasing the remission rate and reducing the recurrence rate can improve the clinical
efficacy of chimeric antigen receptor (CAR) T cell therapy in recurrent/refractory non …

Summary CD19 CAR‐T have emerged as a new standard treatment for relapsed/refractory
(r/r) large B‐cell lymphoma (LBCL). CAR‐T real‐world (RW) outcomes published to date …

Background The administration of second-or third-generation anti-CD19 chimeric antigen
receptor (CAR) T cells has remarkably improved the survival of patients with relapsed or …

The approval of 2 anti-CD19 CAR T-cell therapy products, axicabtagene ciloleucel and
tisagenlecleucel, represents a major advance for the management of patients with relapsed …

Chimeric antigen receptor (CAR)‐T cell therapies have improved the outcome for many
patients with relapsed or refractory aggressive B‐cell lymphomas. In 2017, axicabtagene …